Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023

Precision BioSciences has developed a promising treatment to potentially cure hepatitis B, PBGENE-HBV, which eliminates and inactivates the virus. Preclinical data presented at the AASLD’s Liver Meeting showed the treatment was well-tolerated and engaged with up to 99% of the virus, without any off-target effects. The company aims to file a clinical trial application (CTA) and/or an investigational new drug (IND) application in 2024.